Chewy Gets FDA Warning About Unapproved Antimicrobial Animal Drugs
By Dean Seal
Chewy and eight other manufacturers and distributors of antimicrobial animal drugs have received warning letters from the Food and Drug Administration telling them that those medicines are unapproved and misbranded.
The agency said on Thursday that it's concerned that using the products, which contain antimicrobials that are important in human medicine, without medical oversight contributes to the development of antimicrobial resistance.
The FDA said it hasn't verified the safety or effectiveness of the products as part of an animal drug review process or facility inspections, and that the products are being illegally marketed over the counter. The products are marketed and labeled for minor species such as aquarium fish and pet birds, and contain antimicrobials including amoxicillin and penicillin.
Representatives for Chewy didn't immediately respond to a request for comment.
Among the other companies that received FDA warning letters were Kraft Drug and California Veterinary Supply.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
December 14, 2023 11:19 ET (16:19 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Stocks to Buy While They’re Trading at Big Discounts
-
Markets Brief: Tech Stocks Lead Ahead of Nvidia Earnings
-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
Should You Buy and Hold an Artificial Intelligence Portfolio?
-
3 Cheap and Dependable Dividend-Growth Stocks to Buy
-
The Best Bank Stocks to Buy
-
After Earnings, Is Roblox Stock a Buy, Sell, or Fairly Valued?
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?